HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

Many patients fail to respond to T cell based immunotherapies. Here, the authors, through a high-throughput screening, identify HSP90 inhibitors as a class of preferred drugs for treatment combination with immunotherapy.

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Rina M. Mbofung, Jodi A. McKenzie, Shruti Malu, Min Zhang, Weiyi Peng, Chengwen Liu, Isere Kuiatse, Trang Tieu, Leila Williams, Seram Devi, Emily Ashkin, Chunyu Xu, Lu Huang, Minying Zhang, Amjad H. Talukder, Satyendra C. Tripathi, Hiep Khong, Nikunj Satani, Florian L. Muller, Jason Roszik, Timothy Heffernan, James P. Allison, Gregory Lizee, Sam M. Hanash, David Proia, Rodabe Amaria, R. Eric Davis, Patrick Hwu
Format: article
Langue:EN
Publié: Nature Portfolio 2017
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/51b2a4e16a0b435cabee2477f3975980
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/51b2a4e16a0b435cabee2477f3975980

Documents similaires